IP Library › Granted Patent US 11,752,198
Granted Patent B2
US 11,752,198 · App. 17/115,773 · Granted Sep 12, 2023

GLP-1 compositions and uses thereof

Inventors: Eva Horn Moeller (Alleroed, DK); Michael Duelund Soerensen (Soeborg, DK); Joakim Lundqvist (Malmoe, SE)
Assignee: Novo Nordisk A/S
A61K38/26A61K9/0019A61K9/08A61K47/02A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,752,198
App. No.
17/115,773
Granted
Sep 12, 2023
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Claims (18)

1. A liquid pharmaceutical composition comprising:

semaglutide;

wherein said composition

does not contain phenol;

is for parenteral administration;

is an aqueous solution comprising at least 60% (w/w) water; or

further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; and

wherein the semaglutide is in the range of 0.01 mg/ml-10.0 mg/ml; and

wherein the pH of the composition is in between 7.0 and 7.8;

wherein the liquid pharmaceutical composition exhibits improved chemical and/or physical stability as compared to a liquid pharmaceutical composition that contains phenol.

2. The liquid pharmaceutical composition according to claim 1 , wherein the concentration of semaglutide is selected from 0.5-10 mg/ml or 0.01-5 mg/ml of said composition.

3. The liquid pharmaceutical composition according to claim 1 , wherein said composition comprises no added pharmaceutical preservative.

4. The liquid pharmaceutical composition according to claim 1 , wherein said parenteral administration is subcutaneous administration.

5. A kit comprising the liquid pharmaceutical composition according to claim 1 and instructions for use.

6. A kit comprising the liquid pharmaceutical composition according to claim 1 and an injection device for administration of said composition to a subject, wherein said injection device is selected from the group consisting of a durable pen and a prefilled pen.

7. A method of treating diabetes comprising administering to a subject in need of such method a therapeutically effective amount of the pharmaceutical composition according to claim 1 .

8. A method of treating obesity comprising administering to a subject in need of such method a therapeutically effective amount of the pharmaceutical composition according to claim 1 .

9. The liquid pharmaceutical composition according to claim 1 , wherein said composition has a pH in the range of 7.0-7.4.

Priority Claims (1)
EP 17187676 · Aug 24, 2017 · regional
Continuity (3)
Continuation 16774666 · Jan 28, 2020
Continuation PCTEP2018072835 · Aug 24, 2018
Related Publication 20210085755A1 · Mar 25, 2021
Cited By (9)
US 12,214,017 US 12,233,110 US 12,233,111 US 12,233,112 US 12,337,029 US 12,350,320 US 12,533,315 US 12,636,250 US 12,702,698